← Russell 3000 cross-section

SSII SS Innovations International, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-13, not restated
Healthcare

Scale

Market cap
$710m
Revenue TTM
$52m
Net income TTM
$-12m
Free cash flow
Composite score
Sector rank
#2217

Valuation

P / E
EV / EBITDA
EV / sales
13.3
FCF yield
Earnings yield vs 10-yr
-6.48pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-23.7%
EBITDA margin
-13.4%
ROE
-23.3%
ROIC
-20.8%
Revenue growth
89.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Having commenced commercial sales of our surgical robotic system in the second half of 2022, the year 2023 was our first full year of commercial sales and during the year 2024, we introduced our upgraded SSi Mantra 3 system, further consolidated our installed base of SSi Mantra in various parts of India and began to expand our presence in other global markets. For the three months ended June 30, 2026, we had revenues of $13,939,709 (comprised of $12,361,986 of system sales, $1,142,525 of instrument sales, $419,002 of warranty sales and lease income $16,196), compared to revenues of $10,000,305 (comprising $8,781,038 of system sales, $1,007,830 of instrument sales, $193,359 of warranty sales …SS Innovations International, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-13

Read the full passage →